GlaxoSmithKline : Board and Committee changes - Form 6-K

Board and Committee changes

GSK plc (LSE/NYSE: GSK) has today announced the following changes to its Board and Committees, which took effect immediately following the demerger of the Consumer Healthcare business on Monday 18 July 2022 (the Demerger):

●	Charles Bancrofthas succeeded Vindi Banga as Senior Independent Non-Executive Director. Mr Bancroft has also been appointed a member of the Remuneration Committee.
●	Urs Rohnerhas been appointed a member of the Audit & Risk Committee.
●	Dr Anne Bealhas been appointed a member of the Remuneration and Nominations & Corporate Governance committees.
●	Dr Vishal Sikkawho joined the Board on 18 July 2022 has been appointed a member of the Corporate Responsibility Committee. In addition, Dr Sikka will attend Audit & Risk Committee meetings to support the Committee's oversight of GSK's Digital and Technology programme.

The Board has determined that given the refreshment of the Board following the Demerger and the Company's renewed focus the whole Board will engage with the workforce to gather employees' perspectives rather than designating a specific Non-Executive Director for this purpose. A programme of events is in place to facilitate engagement with employees to gather and understand directly their views.

As previously announced:

●	Vindi Bangaand Dame Vivienne Cox stepped down from the GSK Board upon their appointments to the Haleon plc Board effective on Demerger.
●	Lynn Elsenhansretired from the Board effective from the Demerger.

These changes continue the transition of the Board as an independent biopharma company post separation. GSK expects to announce further Non-Executive Director appointments shortly.

Board and Committee Membership with effect from 18 July 2022:

Board Membership
Sir Jonathan Symonds Emma Walmsley Iain Mackay Dr Hal Barron* Charles Bancroft Dr Anne Beal Dr Hal Dietz Dr Laurie Glimcher Dr Jesse Goodman Urs Rohner Dr Vishal Sikka	Non-Executive Chair Chief Executive Officer Chief Financial Officer Chief Scientific Officer Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director

*Dr Barron will transition to a Non-Independent Non-Executive Director with effect from 1 August 2022.

Board Committee	Committee Chair	Members
Audit & Risk Committee	Charles Bancroft*	Dr Anne Beal Dr Laurie Glimcher Urs Rohner
Remuneration Committee	Urs Rohner	Charles Bancroft Dr Anne Beal
Nominations & Corporate Governance Committee	Sir Jonathan Symonds	Charles Bancroft Dr Anne Beal Urs Rohner
Corporate Responsibility Committee	Dr Anne Beal	Dr Jesse Goodman Dr Vishal Sikka
Science Committee	Dr Jesse Goodman**	Dr Hal Dietz** Dr Laurie Glimcher** Dr Hal Barron (wef 1 August 2022)
Chairs' Committee	Sir Jonathan Symonds	Senior Independent Non-Executive Director Chairs of the Board's Committees

* Audit committee financial expert

** Scientific and Medical Expert

Victoria Whyte

Company Secretary

22 July 2022

Notes

A. The following information is available for reference on www.GSK.com:
1.	Biographies of each Board member	Board of directors and leadership team | GSK
2.	Terms of reference of each Board Committee	Committees | GSK
3.	Current Non-Executive Director Fees	Non-Executive Director Fees
B.	Mr Bancroft's annual feeincreased by £50,000 per annum when he became GSK's Senior Independent Non-Executive Director.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more atgsk.com/company

GSK enquiries
Media:	Tim Foley	[phone]	(London)
	Kathleen Quinn	[phone]	(Washington DC)
Investor Relations:	Nick Stone	[phone]	(London)
	James Dodwell	[phone]	(London)
	Mick Readey	[phone]	(London)
	Josh Williams	[phone]	(London)
	Jeff McLaughlin	[phone]	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS